Generic Name and Formulations:
Clonidine 0.1mg/day, 0.2mg/day, 0.3mg/day; each transdermal patch delivers dose for 1 week.
Boehringer Ingelheim Pharmaceuticals
Indications for CATAPRES-TTS:
Apply to intact, hairless area of upper arm or anterior torso; rotate application sites. Taper withdrawal of other antihypertensives. Initially one 0.1mg/day patch weekly; may increase after 1–2 weeks; max 0.6mg/day.
Sinus node dysfunction. AV block. Pheochromocytoma: not effective. Conduction disturbances. Renal dysfunction. Avoid abrupt cessation. If local reaction occurs from patch, using tabs may cause generalized rash. Discontinue 4hrs before surgery; resume as soon as possible after surgery. Patch: remove before defibrillation, cardioversion, or MRI. Pregnancy (Cat.C). Nursing mothers.
Antagonized by tricyclic antidepressants. Potentiates CNS depressants. Orthostatic regulation disturbances (eg, orthostatic hypotension, dizziness, fatigue) possible with neuroleptics. Monitor heart rate in patients receiving agents known to affect sinus node function or AV nodal conduction (eg, digitalis, calcium channel blockers, β-blockers).
Central alpha agonist.
Dry mouth, dry eye, drowsiness, dizziness, weakness, constipation, sedation, rash, myalgia, urticaria, nausea, insomnia, agitation, orthostatic hypotension, impotence, arrhythmias.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies